Helix BioPharma (TSE:HBP) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Helix BioPharma Corp. has entered into a non-binding letter of intent to acquire the oncology assets of Laevoroc Group, potentially enhancing their immuno-oncology portfolio. The acquisition includes a novel oral chemotherapy formulation and a preclinical immune checkpoint inhibitor, which could simplify cancer treatment and offer new hope for leukemia patients.
For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.
